Humanized Anti-CA IX Antibodies for Specific Low-Toxicity Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CA IX-targeting monoclonal antibodies face challenges such as lack of patient stratification, toxicity, and limited specificity, which hinder their effectiveness in cancer therapy.
Innovation Solution
Development of humanized antibodies with specific CDR sequences that recognize human CA IX, combining murine-derived complementarity determining regions with humanized heavy and light regions, enhancing specificity and safety for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine monoclonal antibodies are used to target CA IX, then therapeutic efficacy is achieved, but toxicity and lack of specificity occur
Solution Approach 1:
The patent applies parameter changes by humanizing the antibody structure - specifically changing the constant regions from murine to human sequences while retaining the variable regions that bind CA IX. This structural parameter change reduces immunogenicity and toxicity while preserving therapeutic efficacy against CA IX-expressing tumors.
Solution Approach 2:
The patent creates a composite antibody structure combining murine variable regions (for CA IX specificity) with human constant regions (for reduced toxicity). This hybrid composite structure achieves both therapeutic efficacy and reduced harmful effects by integrating functional elements from different sources.
2Reliability
If murine monoclonal antibodies are used to target CA IX, then tumor targeting is achieved, but lack of patient stratification occurs
Solution Approach 1:
The patent incorporates feedback mechanisms by including methods for detecting CA IX expression levels in patient tumors. This allows clinicians to stratify patients based on their CA IX status, providing feedback that guides whether the antibody therapy should be administered, thereby preventing treatment of patients who would not benefit.
3Reliability
If conventional monoclonal antibodies are used, then CA IX binding is achieved, but limited specificity occurs
Solution Approach 1:
The patent applies local quality by concentrating the specificity-enhancing features in the variable regions of the antibody, which are the local binding sites that contact CA IX. The humanized constant regions provide a different local quality - reduced immunogenicity - while the variable regions maintain high-specificity binding to CA IX through their specialized structure.
Data Source
AI summary
A humanized antibody specifically recognizing human CA IX, and to therapeutic and diagnostic methods utilizing this antibody is disclosed. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.